ESR1 and breast cancer: In summary, our study shows that glutamine pathway is altered in endocrine resistant breast cancer cell models and co-targeting enhanced glutamine requirement with mTOR (Figure S5) may be useful in impeding growth of this advanced stage of ER+ breast cancer.